Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
S2 E16.1 -- How Cost-Effectiveness Research On Widespread NIT Screening In The U.S. Has Evolved
•
HEP Dynamics
•
Season 2
•
Episode 16
Mazen Noureddin describes how he became engaged in studying the cost-effectiveness of widespread NASH screening for diabetics in the US, and what he has found, while the Surfers comment on the value of this pivotal work.
After Mazen discusses how he became engaged in studying cost effectiveness in screening diabetes patients for NASH, he offers a 30,000-foot view of his findings and shares thoughts on what he plans to study next.
Stephen Harrison and Louise Campbell comment on the exceptional value of his work, after which Roger Green joins Louise in asking how COVID-19 might shape future cost effectiveness estimates.
This ground-breaking work has the potential to expand and redefine the role of population testing in the coming Fatty Liver pandemic.
After Mazen discusses how he became engaged in studying cost effectiveness in screening diabetes patients for NASH, he offers a 30,000-foot view of his findings and shares thoughts on what he plans to study next.
Stephen Harrison and Louise Campbell comment on the exceptional value of his work, after which Roger Green joins Louise in asking how COVID-19 might shape future cost effectiveness estimates.
This ground-breaking work has the potential to expand and redefine the role of population testing in the coming Fatty Liver pandemic.